Our results are generally consistent in direction and magnitude with the existing clinical research, including trials showing reduced heavy alcohol consumption among those with obesity,14 reduced drinking in an experimental bar setting,12 and pharmacoepidemiological analyses showing that GLP-1 receptor agonists are associated with lower incidence and recurrence of alcohol use disorder,2 reduced need for tobacco use related care,5 lower incidence and relapse of cannabis use disorder,4 and reduced risk of opioid overdose in patients with opioid use disorders.8 Our results show that among people with a pre-existing SUD, GLP-1 receptor agonist use was associated with a reduced risk of several adverse clinical outcomes (SUD related emergency department visits, hospital admission, and mortality, drug overdose, and suicidal attempt or ideation)
Results often include a sharper jawline and smoother neck line, enhancing overall facial symmetry
Participants reported greater BMI loss using tirzepatide compared with semaglutide (median 4.75 versus 3.71 kg m 2
Glutathione c nghin cu l c kh nng gii c v gim stress, ngn chn tnh trng oxy ha trong trng hp mc cc bnh mn tnh nh bnh gan do ru, x gan, tn thng gan do nhim virus (HIV/HCV), vim d dy
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
